Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM) will host an investor webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET to announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program.

The live webcast will be available in the investor section of the company's website and will be archived for 60 days after the presentation.

Key Figures

Webcast date: February 24, 2026 Webcast time: 8:00 a.m. ET Archive duration: 60 days

3 metrics

Webcast date February 24, 2026 Investor webcast for Q4 and full-year 2025 results

Webcast time 8:00 a.m. ET Start time of BEAM’s investor webcast

Archive duration 60 days Webcast replay availability on company website

Market Reality Check

Price: $27.59 Vol: Volume 1,163,514 is below...

normal vol

$27.59 Last Close

Volume Volume 1,163,514 is below the 20-day average of 1,512,824 (relative volume 0.77x). normal

Technical Shares at $27.59 are trading above the 200-day MA of $22.73, but remain 24.29% below the 52-week high and 103.99% above the 52-week low.

Peers on Argus

Momentum scanner shows peers like OCUL, TARS, and IRON moving up, while BEAM’s s...

3 Up

Momentum scanner shows peers like OCUL, TARS, and IRON moving up, while BEAM’s specific direction in that scan is not indicated, suggesting stock-specific dynamics around this scheduling notice.

Common Catalyst Peer headlines highlight investor webcasts and data presentations, similar to BEAM’s planned earnings/investor event.

Previous Conferences,earnings Reports

1 past event · Latest: Oct 29 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Oct 29	Earnings call scheduling	Neutral	-0.8%	Announced Q3 2024 earnings call and ASH abstracts webcast timing.

Pattern Detected

Past earnings/conference scheduling produced a small negative move, indicating modest sensitivity to such announcements.

Recent Company History

Recent history for BEAM around combined earnings and conference-call announcements shows limited price impact. On Nov 5, 2024, when the company scheduled a call for Q3 2024 results and ASH abstracts, the stock moved -0.81%. Today’s news again pre-announces timing for financial results and pipeline discussion, fitting a pattern where logistics-focused updates act mainly as informational events rather than major trading catalysts.

Historical Comparison

-0.8% avg move · In the past, BEAM’s combined conferences/earnings scheduling news led to a modest -0.81% move, sugge...

conferences,earnings

-0.8%

Average Historical Move conferences,earnings

In the past, BEAM’s combined conferences/earnings scheduling news led to a modest -0.81% move, suggesting today’s similar webcast announcement typically functions as a low-volatility, informational catalyst.

The company consistently pre-announces webcasts tied to quarterly results and scientific meetings, underscoring a recurring communication pattern rather than a new strategic shift.

Market Pulse Summary

This announcement sets the date and time for Beam’s webcast covering Q4 and full-year 2025 results p...

Analysis

This announcement sets the date and time for Beam’s webcast covering Q4 and full-year 2025 results plus a new liver-targeted genetic disease program. Historically, similar conferences/earnings scheduling (average move -0.81%) has been a low-impact catalyst. Investors may focus on forthcoming details on cash runway, clinical milestones, and the new liver program once disclosed, while monitoring how these align with previously outlined strategic priorities.

Key Terms

investor webcast

1 terms

investor webcast technical

"announce its fourth quarter and full year 2025 financial results ... on an investor webcast"

An investor webcast is a live or archived online presentation where a company’s leaders share financial results, strategy and business updates directly with shareholders and analysts, often accompanied by slides and a question-and-answer segment. Like watching a live TV briefing, it helps investors judge management’s competence and clarify the story behind the numbers, and can change market expectations and a stock’s price.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET.

The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contact:

Holly Manning
Beam Therapeutics
hmanning@beamtx.com

FAQ

When will Beam Therapeutics (BEAM) announce Q4 and full year 2025 results?

Beam will announce Q4 and full year 2025 results on February 24, 2026 at 8:00 a.m. ET. According to the company, the results will be presented during a live investor webcast accessible on the company's investor website and archived for 60 days.

How can investors watch Beam Therapeutics (BEAM) webcast on February 24, 2026?

Investors can watch the live webcast via the company's investor section at www.beamtx.com. According to the company, the presentation will stream live and be archived on the site for 60 days after the event for on-demand viewing.

What topics will Beam Therapeutics (BEAM) cover in the February 24, 2026 webcast?

The webcast will cover Beam's Q4 and full year 2025 financial results and a new liver-targeted genetic disease program. According to the company, presenters will discuss financial results and provide details on the newly announced liver-targeted program during the investor presentation.

Will the Beam Therapeutics (BEAM) February 24, 2026 webcast be available after the live event?

Yes, the webcast will be archived for 60 days following the presentation. According to the company, the archived webcast will remain available in the investor section of the company's website for on-demand access through that 60-day window.

Is the February 24, 2026 Beam Therapeutics (BEAM) webcast open to all investors?

The webcast is publicly accessible via the company's investor website at www.beamtx.com. According to the company, investors and other interested parties can access the live stream and the subsequent 60-day archived recording on that site.

What new program will Beam Therapeutics (BEAM) announce on February 24, 2026?

Beam will announce a new liver-targeted genetic disease program during the webcast on February 24, 2026. According to the company, details about the program's focus and next steps will be provided in the investor presentation alongside financial results.